company background image
SPRO

Spero Therapeutics NasdaqGS:SPRO Stock Report

Last Price

US$1.44

Market Cap

US$47.3m

7D

-15.3%

1Y

-89.4%

Updated

18 May, 2022

Data

Company Financials +
SPRO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SPRO Stock Overview

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

Spero Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Spero Therapeutics
Historical stock prices
Current Share PriceUS$1.44
52 Week HighUS$19.87
52 Week LowUS$1.43
Beta1.86
1 Month Change-74.69%
3 Month Change-84.26%
1 Year Change-89.44%
3 Year Change-88.30%
5 Year Changen/a
Change since IPO-87.48%

Recent News & Updates

Shareholder Returns

SPROUS BiotechsUS Market
7D-15.3%5.7%0.5%
1Y-89.4%-21.4%-11.5%

Return vs Industry: SPRO underperformed the US Biotechs industry which returned -19.5% over the past year.

Return vs Market: SPRO underperformed the US Market which returned -8.1% over the past year.

Price Volatility

Is SPRO's price volatile compared to industry and market?
SPRO volatility
SPRO Average Weekly Movement21.6%
Biotechs Industry Average Movement12.4%
Market Average Movement7.9%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: SPRO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: SPRO's weekly volatility has increased from 13% to 22% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201335Ankit Mahadeviahttps://sperotherapeutics.com

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd.

Spero Therapeutics Fundamentals Summary

How do Spero Therapeutics's earnings and revenue compare to its market cap?
SPRO fundamental statistics
Market CapUS$47.26m
Earnings (TTM)-US$103.16m
Revenue (TTM)US$13.03m

3.6x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SPRO income statement (TTM)
RevenueUS$13.03m
Cost of RevenueUS$63.09m
Gross Profit-US$50.07m
Other ExpensesUS$53.09m
Earnings-US$103.16m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.14
Gross Margin-384.40%
Net Profit Margin-792.03%
Debt/Equity Ratio0%

How did SPRO perform over the long term?

See historical performance and comparison

Valuation

Is Spero Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: SPRO ($1.44) is trading below our estimate of fair value ($97.5)

Significantly Below Fair Value: SPRO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SPRO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SPRO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SPRO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SPRO is good value based on its PB Ratio (0.8x) compared to the US Biotechs industry average (1.5x).


Future Growth

How is Spero Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


29.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SPRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SPRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SPRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SPRO's revenue (52% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: SPRO's revenue (52% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SPRO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Spero Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-21.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SPRO is currently unprofitable.

Growing Profit Margin: SPRO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SPRO is unprofitable, and losses have increased over the past 5 years at a rate of 21% per year.

Accelerating Growth: Unable to compare SPRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: SPRO has a negative Return on Equity (-165.13%), as it is currently unprofitable.


Financial Health

How is Spero Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SPRO's short term assets ($132.7M) exceed its short term liabilities ($69.2M).

Long Term Liabilities: SPRO's short term assets ($132.7M) exceed its long term liabilities ($14.2M).


Debt to Equity History and Analysis

Debt Level: SPRO is debt free.

Reducing Debt: SPRO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SPRO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SPRO has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 18% each year.


Dividend

What is Spero Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SPRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SPRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SPRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SPRO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SPRO has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Ankit Mahadevia (40 yo)

9.33yrs

Tenure

US$4,875,045

Compensation

Dr. Ankit Mahadevia, MD, MBA serves as the Chief Executive Officer and President of Spero Therapeutics, LLC. Dr. Mahadevia Co-founded of Spero Therapeutics, Inc. in 2013 and has been its Chief Executive Of...


CEO Compensation Analysis

Compensation vs Market: Ankit's total compensation ($USD4.88M) is above average for companies of similar size in the US market ($USD771.97K).

Compensation vs Earnings: Ankit's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: SPRO's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: SPRO's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.


Top Shareholders

Company Information

Spero Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Spero Therapeutics, Inc.
  • Ticker: SPRO
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$47.263m
  • Shares outstanding: 32.82m
  • Website: https://sperotherapeutics.com

Number of Employees


Location

  • Spero Therapeutics, Inc.
  • 675 Massachusetts Avenue
  • 14th Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/18 00:00
End of Day Share Price2022/05/18 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.